Every material Form 8-K Adagio Medical Holdings, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Adagio Medical said its board has begun a formal process to explore strategic alternatives, including a possible acquisition, merger or other transaction, and is reducing its workforce by 25 of 43 full-time employees effective September 23, 2026. The company also said it will lower the conversion price on its 13% Senior Secured Convertible Notes from September 23, 2026 through October 31, 2026, which could result in more shares being issued on conversion, and that there is no assurance any transaction will occur.
Workforce reduction of 25 of 43 full-time employees, effective September 23, 2026
Estimated cash expenditures of approximately $1.3 million, mainly one-time severance, benefits and related costs; additional charges, including possible impairments, cannot yet be estimated
Conversion price on the 13% Senior Secured Convertible Notes to be lowered for conversions from September 23, 2026 through October 31, 2026, subject to extension
Preliminary unaudited cash, equivalents and marketable securities of approximately $7.7 million as of June 30, 2026; no timetable set for the strategic review
Adagio Medical Holdings received a Nasdaq deficiency letter on August 13, 2026, saying it does not meet the minimum $2,500,000 stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company reported stockholders' equity of $(415,000) in its June 30, 2026 quarterly report, and the notice has no immediate effect on its listing. Shareholders should note the company must submit a compliance plan by September 28, 2026, and the company's filing cites going concern and financing risks.
Nasdaq notice received August 13, 2026 for stockholders' equity below $2,500,000 minimum
Reported stockholders' equity of $(415,000) in Form 10-Q for period ended June 30, 2026
Compliance plan due by September 28, 2026; Staff may grant up to 180 calendar days to regain compliance if plan is accepted
Company does not meet alternative standards of $35 million market value of listed securities or $500,000 net income
Adagio Medical Holdings furnished an updated corporate presentation for investor, analyst and other meetings, attached as Exhibit 99.1 to a Form 8-K. The filing is a Regulation FD disclosure with no financial results, guidance or transaction terms, so it contains no new reported financial figures.
Updated corporate presentation dated August 13, 2026, made available on the company website and attached as Exhibit 99.1.
Presentation cites FDA approval of vCLAS expected Q4 2026 and of next-generation vCLAS Ultra expected Q1 2028, per company timeline.
Presentation lists cash and cash equivalents of $7.7 million and convertible notes payable of $24.8 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Adagio Medical Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →